Number of eligible people: CDEC discussed the uncertainty in the volume of people with reasonably critical to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some patients who will be labeled as possessing gentle or average disorder could possibly have a critical https://hemgenix05260.qowap.com/95113389/the-best-side-of-hemgenix